Factors Influencing Blood Concentration of Voriconazole and Therapeutic Drug Monitoring in Patients with Child–Pugh Class C Cirrhosis
Table 4
Characteristics of and clinical course in patients with voriconazole-related adverse events (AEs).
Patient
Sex
Age (years)
Cause of liver cirrhosis
Voriconazole maintenance dose (daily)
Voriconazole Cmin(μg/mL)
AEs; NCI-CTCAE grade
Duration of voriconazole therapy at time of AE (days)
Modification to voriconazole therapy
Assessment of AEs after modification or discontinuation of voriconazole (days of follow-up)
1
F
54
Primary biliary cholangitis
200 mg twice
11
ALT↑, AST↑; NCI-CTCAE grade 2
6
100 mg twice after AE
ALT and AST fell below under the ULN (13 days after decreased dosage)
2
M
49
Hepatitis B
100 mg twice
6.52
AST↑, ALP↑; NCI-CTCAE grade 1
9
No change
NA (patient died during voriconazole therapy)
3
M
56
Hepatitis B
200 mg twice
8.5
AST↑, ALP↑; NCI-CTCAE grade 1
30
No change
NA (no AST and ALP data after discontinuation)
4
M
59
Hepatitis B
200 mg twice
4.95
Consciousness disturbance; NCI-CTCAE grade 2
4
100 mg twice after AE
Consciousness returned to normal (2 days after dosage reduced)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; F, female; M, male; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; ULN, upper limit of normal.
